105565-55-7 Usage
Uses
BMY 14802 Hydrochloride was studied to be a potential atypical antipsychotic agent.
Biological Activity
Potent sigma receptor antagonist (IC 50 = 112 nM) with modest to weak affinity for 5-HT 1A and α 1 receptors. Antipsychotic following oral administration and acts via indirect modulation of central dopaminergic systems.
in vitro
bmy 14802 has its most potent binding at the sigma binding site, with some degree of serotonin subtype 1a and negligible dopamine receptor binding [1].
in vivo
bmy 14802 is atypical of standard neuroleptics in that it does not induce catalepsy in rats. in addition, it has been shown to have efficacy in animal models of psychosis [1].
IC 50
112 nm for (+)-[3h]-3-ppp
references
[1] gewirtz gr, gorman jm, volavka j, macaluso j, gribkoff g, taylor dp, borison r. bmy 14802, a sigma receptor ligand for the treatment of schizophrenia. neuropsychopharmacology. 1994 feb;10(1):37-40.
Check Digit Verification of cas no
The CAS Registry Mumber 105565-55-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,5,5,6 and 5 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 105565-55:
(8*1)+(7*0)+(6*5)+(5*5)+(4*6)+(3*5)+(2*5)+(1*5)=117
117 % 10 = 7
So 105565-55-7 is a valid CAS Registry Number.
InChI:InChI=1/C18H22F2N4O.ClH/c19-15-5-3-14(4-6-15)17(25)2-1-7-23-8-10-24(11-9-23)18-21-12-16(20)13-22-18;/h3-6,12-13,17,25H,1-2,7-11H2;1H
105565-55-7Relevant academic research and scientific papers
Agents for treatment of brain ischemia
-
, (2008/06/13)
A series of 5-halopyrimidin-2-ylpiperazinylalkyl derivatives having useful anti-ischemic properties for treatment and prevention of dirorders resulting from brain and/or spinal cord anoxia.
Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
-
, (2008/06/13)
Disubstituted N,N-piperazinyl derivatives are disclosed wherein one substituent is a pyrimidin-2-yl ring and the other is a 4 carbon chain attached to a p-fluorophenyl ring at the terminal carbon. The terminal carbon of this butylene chain is also bonded to an oxygen atom as part of a carbonyl, carbinol, or ketal functionality. These compounds possess psychotropic properties, particularly atypical antipsychotic activity of good duration. By virtue of pre-clinical pharmacological testing, these compounds appear useful as potential antipsychotic agents which lack the typical movement disorder side-effects of standard antipsychotic agents.
